Ligand-based pharmacophore exploration and QSAR analysis of transition state analogues followed by in silico screening guide the discovery of new sub-micromolar β-secreatase inhibitors

Medicinal Chemistry Research

Volumn 22, Issue 4, 2013, Pages 1979-1997

  Al Nadaf, Afaf ^a   Taha, Mutasem O ^b  

^a APPLIED SCIENCE PRIVATE UNIVERSITY   (Jordan)

^b UNIVERSITY OF JORDAN   (Jordan)

Author keywords

Secretase inhibitors; Alzheimer's; Pharmacophore modeling; Quantitative structure activity relationship; Transition state

Indexed keywords

BETA SECRETASE INHIBITOR; DIMETHYL SULFOXIDE; HYDROXYL GROUP; LIGAND;

ARTICLE; BIOLOGICAL ACTIVITY; COMPUTER MODEL; CONFORMATIONAL TRANSITION; FLUORESCENCE RESONANCE ENERGY TRANSFER; GENETIC ALGORITHM; IN VITRO STUDY; PHARMACOPHORE; PHYSICAL CHEMISTRY; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RECEIVER OPERATING CHARACTERISTIC;

EID: 84879690342     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-012-0204-x     Document Type: Article

References (66)

1. Abdula AM, Khalaf RA, Mubarak MS, Taha MO (2011) Discovery of new β-D-galactosidase inhibitors via pharmacophore modeling and QSAR analysis followed by in silico screening. J Comput Chem 32:463-482
2. Abu Hammad AM, Taha MO (2009) Pharmacophore modelling, quantitative structure-activity relationship analysis and shape-complemented in silico screening allow access to novel influenza neuraminidase inhibitors. J Chem Inf Model 49:978
3. Abu Khalaf R, Abu Sheikha G, Bustanji Y, Taha MO (2010) Discovery of new cholesteryl ester transfer protein inhibitors via ligand-based pharmacophore modeling and QSAR analysis followed by synthetic exploration. Eur J Med Chem 45:1598-1617
4. Abu Khalaf R, Abu Sheikha G, Bustanji Y, Taha MO (2011) Discovery of new β-D-glucosidase inhibitors via pharmacophore modeling and QSAR analysis followed by in silico screening. J Mol Model 17:443-464
5. Accelrys, Inc. (2005) CERIUS2, version 4.10 QSAR Users' Manual. Accelrys, Inc, San Diego, pp 221-235
6. Al-Nadaf A, Taha MO (2011) Discovery of new rennin inhibitory leads via sequential pharmacophore modeling, QSAR analysis, in silico screening and in vitro evaluation. J Mol Graph Model 29:843-864
7. Al-Nadaf A, Abu Sheikha G, Taha MO (2010) Elaborate ligand-based pharmacophore exploration and QSAR analysis guide the synthesis of novel pyridinium-based potent beta-secretase inhibitory leads Bioorg. Med Chem 18:3088-3115
8. Al-Sha'er M, Taha MO (2010) Elaborate ligand-based modeling reveals new nanomolar heat shock protein 90α inhibitors. Eur J Med Chem 45:4316-4330
9. Amyes T, Richard J (2007) Rational design of transition-state analogues as potent enzyme inhibitors with therapeutic applications. ACS Chem Biol 2:711-714
10. Arun KG, Geoffrey B, Cynthia H, Reiko K, Dongwoo S, Khaja A, Lin H, Jeffrey AL, Chan N, Gerald K, Jacques E, Jordan T (2001) Structure-based design: potent Inhibitors of human brain memapsin 2 (β-secretase). J Med Chem 44:2865
11. Beeley NRA, Sage C (2003) GPCRs: an update on structural approaches to drug discovery. Targets 2:19-25
12. Bemis GW, Murcko MA (1996) The properties of known drugs. 1. Molecular frame-works. J Med Chem 39:2887-2893
13. Bersuker IB, Bahçeci S, Boggs JE (2000) Pharmacophore perception, development and use in drug design. International University Line, San Diego, pp 457-473
14. Beswick P, Charrier N, Clarke B, Demont E, Dingwall C, Dunsdon R, Faller A, Gleave R, Hawkins J, Hussain I, Johnson CN, Macpherson D, Maile G, Matico R, Milner P, Mosley J, Naylor A, O'Brien A, Redshaw S, Riddell D, Rowland P, Skidmore J, Soleil V, Smith KJ, Stanway S, Stemp G, Stuart A, Sweitzer S, Theobald P, Vesey D, Walter DS, Ward J, Wayne G (2008) BACE-1 inhibitors part 3: identification of hydroxy ethylamines (HEAs) with nanomolar potency in cells. Bioorg Med Chem Lett 18:1022
15. Catalyst User Guide, Version 4.11 (2005) Accelrys Software Inc., San Diego
16. Charrier N, Clarke B, Cutler L, Demont E, Dingwall C, Dunsdon R, Hawkins J, Howes C, Hubbard J, Hussain I, Maile G, Matico R, Mosley J, Naylor A, O'Brien A, Redshaw S, Rowland P, Soleil V, Smith KJ, Sweitzer S, Theobald P, Vesey D, Walter DS, Wayne G (2009a) Second generation of BACE-1 inhibitors. Part 1 The need for improved pharmacokinetics. Bioorg Med Chem Lett 19:3664
17. Charrier N, Clarke B, Demont E, Dingwall C, Dunsdon R, Hawkins J, Hubbard J, Hussain I, Maile G, Matico R, Mosley J, Naylor A, O'Brien A, Redshaw S, Rowland P, Soleil V, Smith KJ, Sweitzer S, Theobald P, Vesey D, Walter DS, Wayne G (2009b) Second generation of BACE-1 inhibitors part 2: optimisation of the non-prime side substituent. Bioorg Med Chem Lett 19:3669
18. Charrier N, Clarke B, Cutler L, Demont E, Dingwall C, Dunsdon R, Hawkins J, Howes C, Hubbard J, Hussain I, Maile G, Matico R, Mosley J, Naylor A, O'Brien A, Redshaw S, Rowland P, Soleil V, Smith KJ, Sweitzer S, Theobald P, Vesey D, Walter DS, Wayne G (2009c) Second generation of BACE-1 inhibitors part 3: towards non hydroxyethylamine transition state mimetics. Bioorg Med Chem Lett 19:3674
19. Clarke B, Demont E, Dingwall C, Dunsdon R, Faller A, Hawkins J, Hussain I, Macpherson D, Maile G, Matico R, Milner P, Mosley J, Naylor A, O'Brien A, Redshaw S, Riddell D, Rowland P, Soleil V, Smith K, Stanway S, Stemp G, Sweitzer S, Theobald P, Vesey D, Walter DS, Ward J, Wayne G (2008a) BACE-1 inhibitors part 2: identification of hydroxy ethylamines (HEAs) with reduced peptidic character. Bioorg Med Chem Lett 18:1017
20. Clarke B, Demont E, Dingwall C, Dunsdon R, Faller A, Hawkins J, Hussain I, Macpherson D, Maile G, Matico R, Milner P, Mosley J, Naylor A, O'Brien A, Redshaw S, Riddell D, Rowland P, Soleil V, Smith K, Stanway S, Stemp G, Sweitzer S, Theobald P, Vesey D, Walter DS, Ward J, Wayne G (2008b) BACE-1 inhibitors part 1: identification of novel hydroxy ethylamines (HEAs). Bioorg Med Chem Lett 18:1011
21. Cooper JB (2002) Aspartic proteinases in disease: a structural perspective. Curr Drug Targets 3:155-173
22. Cumming JN, Le TX, Babu S, Carroll X, Chen L, Favreau P, Gaspari T, Guo DW, Hobbs Y, Huang U, Iserloh M (2008) Rational design of novel, potent piperazinone and imidazolidinone BACE1 inhibitors. Bioorg Med Chem Lett 18:3236
23. DePristo MA, de Bakker PIW, Blundell TL (2004) Heterogeneity and inaccuracy in protein structures solved by X-ray crystallography. Structure 12:831-838
24. 3 substrate binding pockets. Bioorg Med Chem Lett 18:1063
25. Discovery Studio 2.5.5 User Guide (2010)
26. Fisher R (1966) The principle of experimentation illustrated by a psycho-physical experiment, 8th edn. Hafner Publishing Co, New York
27. Gao H, Williams C, Labute P, Bajorath J (1999) Binary quantitative structure-activity relationships (QSAR) analysis of estrogen receptor ligands. J Chem Inf Comput Sci 39:164-168
28. Georgia BM, Dennis C, Samuel LG, Ming-Tain L, Sanjeev KM, Philippe GN, Beth P, Hemaka AR, Harold GS, Shaun RS, Katharine MH (2007) β-Secretase (BACE-1) inhibitors: accounting for 10 s loop flexibility using rigid active sites. Bioorg Med Chem Lett 17:1117
29. Godemann R, Madden J, Kramer J, Smith MA, Fritz U, Hesterkamp T, Barker J, Hoeppner S, Hallett D, Cesura A, Ebneth A, Kemp J (2009) Fragment-based discovery of BACE1 inhibitors using functional assays. Biochemistry 48:10743
30. Hahn M (1997) Three-dimensional shape-based searching of conformationally flexible compounds. J Chem Inf Comput Sci 37:80-86
31. Heuisul P, Kyeongsik M, Hyo-Shin K, Ki DK, Dongchul L, Sang-Won S, Jae-Ung C, Bettina P, Deog-Young C (2008) Synthesis, SAR, and X-ray structure of human BACE-1 inhibitors with cyclic urea derivatives. Bioorg Med Chem Lett 18:2900
32. Huang D, Urs L, Peter K, Marco C, Alcide B, Amedeo C (2006) In silico discovery of β-secretase inhibitors. J Am Chem Soc 128:5436
33. Huang W, Yu H, Sheng R, Li J, Hu Y (2008) Identification of pharmacophore model, synthesis and biological evaluation of N-phenyl-1-arylamide and N-phenylbenzenesulfonamide derivatives as BACE 1 inhibitors. Bioorg Med Chem 16:10190
34. Irwin JJ, Shoichet BK (2005) ZINC - a free database of commercially available compounds for virtual screening. J Chem Inf Comput Sci 45:177-182
35. Jacobsson M, Liden P, Stjernschantz E, Bostroem H, Norinder U (2003) Improving structure-based virtual screening by multivariate analysis of scoring data. J Med Chem 46:5781-5789
36. Kirchmair J, Markt P, Distinto S, Wolber G, Langer T (2008) Evaluation of the performance of 3D virtual screening protocols: rMSD comparisons, enrichment assessments, and decoy selection - what can we learn from earlier mistakes? J Comput Aided Mol 22:213-228
37. Klebe G (2006) Virtual ligand screening: strategies, perspectives and limitations. Drug Discovery Today 11:580-594
38. Kurogi Y, Güner O (2001) Pharmacophore modeling and threedimensional database searching for drug design using catalyst Curr. Med Chem 8:1035
39. Li H, Sutter J, Hoffmann R (2000) Pharmacophore perception, development, and use in drug design. International University Line, San Diego, pp 173-189
40. Lorna P, Andrea C, Francesco C, Federica B, Manuela B, Francesca M, Maurizio R, Vincenza A, Angela R (2008) Multi-target-directed coumarin derivatives: hAChE and BACE1 inhibitors as potential anti-Alzheimer compounds. Bioorg Med Chem Lett 18:423
41. Maria LB, Riccardo M, Anna M, Michela R, Carlo M (2009) Alzheimer's disease: new approaches to drug discovery. Curr Opin Chem Biol 13:303
42. Moffat K, Gillet VJ, Whittle M, Bravi G, Leach ARA (2008) A comparison of field-based similarity searching methods: catShape, FBSS, and ROCS. J Chem Inf Model 48:719-729
43. Poptodorov K, Luu T, Langer T, Hoffmann R (2006) Methods and principles in medicinal chemistry, pharmacophores and pharmacophores searches, vol 2. Wiley-VCH, Weinheim, pp 17-47
44. Ramsey LF, Schafer WD (1997) The statistical sleuth, 1st edn. Wadsworth Publishing Company, Belmont
45. Rizzi L, Vaiana N, Sagui F, Genesio E, Pilli E, Porcari V, Romeo S (2009) Design, synthesis and docking studies of hydroxyethylamine and hydroxyethylsulfide BACE-1 inhibitors. Protein Pept Lett 16(5):86-90
46. Schramm V (2003) Enzymatic transition state poise and transition state analogues. Acc Chem Res 36:588-596
47. Schramm V (2005) Enzymatic transition states and transition state analogues. Curr Opin Struct Biol 15:604-613
48. Shawn JS (2009) Progress toward the development of a viable BACE-1 inhibitor. Drug Dev Res 70:101
49. Sheridan RP, Kearsley SK (2002) Why do we need so many chemical similarity search methods. Drug Discovery Today 7:903-911
50. Singh J, Chuaqui CE, Boriack-Sjodin PA, Lee W, Pontz T, Corbley MJ, Cheung H, Arduini RM, Mead JN, Newman MN, Papadatos JL, Bowes S, Josiah S, Ling LE (2003) Successful shape-based virtual screening: the discovery of a potent inhibitor of the type I TGFβ receptor kinase (TβRI). Bioorg Med Chem Lett 13:4355-4359
51. Smellie A, Teig S, Towbin P (1995) Poling: promoting conformational variation. J Comput Chem 16:171
52. Sprague PW, Hoffmann R (1997) CATALYST pharmacophore models and their utility as queries for searching 3D databases. In: Van de Waterbeemd H, Testa B, Folkers G (eds) Computer assisted lead finding and optimization. Verlag Helvetica Chimica Acta, Zürich, pp 223-240
53. Steuber H, Zentgraf M, Gerlach C, Sotriffer CA, Heine A, Klebe G (2006) Expect the unexpected or caveat for drug designers: multiple structure determinations using aldose reductase crystals treated under varying soaking and co-crystallisation conditions. J Mol Biol 363:174-187
54. Stubbs MT, Reyda S, Dullweber F, Moller M, Klebe G, Dorsch D, Mederski W, Wurziger H (2002) pH-dependent binding modes observed in trypsin crystals: lessons for structure-based drug design. ChemBioChem 3:246-249
55. Sutter J, Güner O, Hoffmann R, Li H, Waldman M (2000) Effect of variable weights and tolerances on predictive model generation. In: Güner OF (ed) Pharmacophore perception, development, and use in drug design. International University Line, San Diego, pp 501-511
56. Taha MO, Bustanji Y, Al-Bakri AG, Yousef M, Zalloum WA, Al-Masri IM, Atallah N (2007) Discovery of new potent human protein tyrosine phosphatase inhibitors via pharmacophore and QSAR analysis followed by in silico screening. J Mol Graph Modell 25:870-884
57. Taha MO, Atallah N, Al-Bakri AG, Paradis-Bleau C, Zalloum H, Younis K, Levesque RC (2008a) Discovery of new murf inhibitors via pharmacophore modeling and QSAR analysis followed by in silico screening. Bioorg Med Chem 16:1218-1235
58. Taha MO, Bustanji Y, Al-Ghussein M, Mohammad M, Zalloum H, Al-Masri IM, Atallah N (2008b) Pharmacophore modeling, quantitative structure-activity relationship analysis, and in silico screening reveal potent glycogen synthase kinase-3beta inhibitory activities for cimetidine, hydroxychloroquine, and gemifloxacin. J Med Chem 51:2062-2077
59. Taha MO, Dahabiyeh LA, Bustanji Y, Zalloum H, Saleh S (2008c) Combining ligand-based pharmacophore modeling, QSAR analysis and in silico screening for the discovery of new potent hormone sensitive lipase inhibitors. J Med Chem 51:6478-6494
60. Taha MO, Habash M, Al-Hadidi Z, Al-Bakri A, Younis K, Sisan S (2011) Docking-based comparative intermolecular contacts analysis as new 3-D QSAR concept for validating docking studies and in silico screening: nMT and GP inhibitors as case studies. J Chem Inf Model 51:647-669
61. Triballeau N, Acher F, Brabet I, Pin J-P, Bertrand H-O (2005) Virtual screening workflow development guided by the "receiver operating characteristic" curve approach. Application to highthroughput docking on metabotropic glutamate receptor subtype 4. J Med Chem 48:2534-2547
62. Varghese J (2006) Human beta-secretase (BACE) and BACE inhibitors: progress report. Curr Top Med Chem 6:569
63. Verdonk ML, Marcel L, Berdini V, Hartshorn MJ, Mooij WTM, Murray CW, Taylor RD, Watson P (2004) Virtual screening using protein-ligand docking: avoiding artificial enrichment. J Chem Inf Comput Sci 44:793-806
64. Wen-Hai H, Rong S, Yong-Zhou H (2009) Progress in the development of nonpeptidomimetic BACE 1 inhibitors for Alzheimers disease. Curr Med Chem 16:1806
65. Yoshiari S, Takeshi K, Akinori A, Tetsuhiro N, Hachiro S (2008) Flavonols and flavones as BACE-1 inhibitors: structure-activity relationship in cell-free, cell-based and in silico studies reveal novel pharmacophore features. Biochim Biophys Acta 1780:819
66. Yoshio H, Hiroko O, Naoko M, Ryoji Y, Abdellah Y, Koushi H, Tooru K, Kazuki S, Yoshio H, Shoichi I, Yoshiaki K (2008) Novel non-peptidic and small-sized BACE1 inhibitors. Bioorg Med Chem Lett 18:1654